Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

CADL

Candel Therapeutics (CADL)

Candel Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CADL
DateTimeSourceHeadlineSymbolCompany
05/30/20244:20PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CADLCandel Therapeutics Inc
05/30/20243:30PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CADLCandel Therapeutics Inc
05/30/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
05/30/20247:00AMGlobeNewswire Inc.FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
05/24/20246:30AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
05/23/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
05/23/20244:00PMGlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
05/22/20247:00AMGlobeNewswire Inc.Candel Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CADLCandel Therapeutics Inc
05/20/20247:00AMGlobeNewswire Inc.Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
05/14/20247:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CADLCandel Therapeutics Inc
05/14/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
05/14/20247:00AMGlobeNewswire Inc.Candel Therapeutics Reports First Quarter 2024 Financial ResultsĀ and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
04/25/20247:00AMGlobeNewswire Inc.Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
04/11/20248:00AMGlobeNewswire Inc.Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
04/09/20247:00AMGlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsNASDAQ:CADLCandel Therapeutics Inc
04/04/20247:00AMGlobeNewswire Inc.Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
03/28/20243:05PMGlobeNewswire Inc.Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
03/28/20247:05AMGlobeNewswire Inc.Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
03/06/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
03/05/20243:30PMGlobeNewswire Inc.Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateNASDAQ:CADLCandel Therapeutics Inc
02/13/20248:00AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
02/13/20246:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
02/13/20246:30AMGlobeNewswire Inc.CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
02/05/20247:00AMGlobeNewswire Inc.Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and CatalystsNASDAQ:CADLCandel Therapeutics Inc
01/19/20247:30AMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
01/12/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
01/03/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
12/12/20237:58AMDow Jones NewsCandel Therapeutics Shares Soar After FDA Fast Track of CAN-2409NASDAQ:CADLCandel Therapeutics Inc
12/12/20237:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
12/12/20237:00AMGlobeNewswire Inc.Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CADL